Peptide-metal nanohybrids (PMN): Promising entities for combating neurological maladies
- PMID: 37487364
- DOI: 10.1016/j.cis.2023.102954
Peptide-metal nanohybrids (PMN): Promising entities for combating neurological maladies
Abstract
Nanotherapeutics are gaining traction in the modern scenario because of their unique and distinct properties which separate them from macro materials. Among the nanoparticles, metal NPs (MNPs) have gained importance due to their distinct physicochemical and biological characteristics. Peptides also exhibit several important functions in humans. Different peptides have received approval as pharmaceuticals, and clinical trials have been commenced for several peptides. Peptides are also used as targeting ligands. Considering all the advantages offered by these two entities, the conjugation of MNPs with peptides has emerged as a potential strategy for achieving successful targeting, diagnosis, and therapy of various neurological pathologies.
Keywords: Alzheimer's disease; Blood-brain barrier; Metal nanoparticles (MNPs); Neurological disorders; Peptide.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no competing financial interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
